ClinicalTrials.gg

Program

Octreotide

Also written as “Sandostatin LAR Depot”, “Octreotide LAR” and “Sandostatin LAR”.

Its studies are mostly in Acromegaly · Obesity · Diarrhea · Malignant Carcinoid Syndrome · Thymoma, led by 5 companies.

Furthest: phase 4, since Dec 17, 200230 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis210 open or runningphase 4since Dec 17, 2002Nov 2, 1999none ahead
Keenova Therapeutics40 open or runningphase 3since Sep 30, 2008Sep 30, 2008none ahead
Chiesi Farmaceutici30 open or runningphase 3since Aug 5, 2011Aug 5, 2011none ahead
Ambrilia Biopharma10 open or runningphase 3since Mar 21, 2008Mar 21, 2008none ahead
Dauntless Pharmaceuticals10 open or runningphase 1since Jan 17, 2017Jan 17, 2017none ahead

Also a collaborator on its studies: quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Nov 2, 1999.

  1. Sep 6, 2006Phase 3 study in AcromegalyNovartis · NCT00372697 · 28 enrolled · Italy
  2. Sep 13, 2006Phase 4 study in AcromegalyNovartis · NCT00376064 · 20 enrolled · Germany
  3. Dec 21, 2007Phase 1 study in Irritable Bowel SyndromeNovartis · NCT00584298 · 50 enrolled · United States, Canada, Sweden and more
  4. Dec 21, 2007Phase 3 study in Colorectal NeoplasmsNovartis · NCT00582426 · 139 enrolled · Brazil
  5. Mar 21, 2008Ambrilia Biopharma's first study: phase 3 study in AcromegalyNew to Ambrilia BiopharmaAmbrilia Biopharma · NCT00642421 · 40 enrolled · United States, Belarus, Hungary and more
  6. May 15, 2008Phase 3 study in Carcinoid TumorNovartis · NCT00690430 · 186 enrolled · United States, Argentina, Austria and more
  7. Sep 30, 2008Keenova Therapeutics's first study: phase 3 study in AcromegalyNew to Keenova TherapeuticsKeenova Therapeutics · NCT00765323 · 169 enrolled · United States, Czech Republic, Germany and more
  8. Apr 20, 2009Phase 2 study in Serotonin SyndromeKeenova Therapeutics · NCT00884715 · 10 enrolled · United States
  9. May 26, 2009Phase 2 study in AcromegalyKeenova Therapeutics · NCT00913055 · 34 enrolled
  10. Feb 10, 2011Phase 3 study in AcromegalyKeenova Therapeutics · NCT01295060 · 12 enrolled · United States
  11. Aug 5, 2011Chiesi Farmaceutici's first study: phase 3 study in AcromegalyNew to Chiesi FarmaceuticiChiesi Farmaceutici · NCT01412424 · 155 enrolled · United States, Germany, Hungary and more
  12. Jan 28, 2016Phase 3 study in AcromegalyChiesi Farmaceutici · NCT02685709 · 146 enrolled · United States, Austria, France and more
  13. Jan 17, 2017Dauntless Pharmaceuticals's first study: phase 1 study in Healthy Volunteer StudyNew to Dauntless PharmaceuticalsDauntless Pharmaceuticals · NCT03031535 · 32 enrolled · United States
  14. Aug 10, 2017Phase 3 study in AcromegalyChiesi Farmaceutici · NCT03252353 · 56 enrolled · United States, Australia, Bulgaria and more

TargetBeta

“Somatostatin receptor agonist”ChEMBL 37, by rule

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT03252353Acromegaly · United States, Australia, Bulgaria and more3UNKNOWNChiesi FarmaceuticiJun 13, 201956
NCT03031535Healthy Volunteer Study · United States1CompletedDauntless PharmaceuticalsMar 201732
NCT02685709Acromegaly · United States, Austria, France and more3CompletedChiesi FarmaceuticiOct 2020146
NCT01412424Acromegaly · United States, Germany, Hungary and more3CompletedChiesi FarmaceuticiMay 2014155
NCT01295060Acromegaly · United States3TerminatedKeenova TherapeuticsApr 201212
NCT00913055Acromegaly2CompletedKeenova TherapeuticsMay 200734
NCT00884715Serotonin Syndrome · United States2TerminatedKeenova TherapeuticsNov 201110
NCT00765323Acromegaly · United States, Czech Republic, Germany and more3TerminatedKeenova TherapeuticsFeb 2011169
NCT00690430Carcinoid Tumor · United States, Argentina, Austria and more3CompletedNovartisApr 2012186
NCT00642421Acromegaly · United States, Belarus, Hungary and more3TerminatedAmbrilia BiopharmaAug 200940
NCT00584298Irritable Bowel Syndrome · United States, Canada, Sweden and more1CompletedNovartisApr 200950
NCT00582426Colorectal Neoplasms · Brazil3CompletedNovartisSep 2010139
NCT00376064Acromegaly · Germany4CompletedNovartisJan 201020
NCT00372697Acromegaly · Italy3CompletedNovartisOct 200728
NCT00332969Thymoma · Germany2CompletedNovartisOct 201025
NCT00332696Peritoneal Neoplasms · France2CompletedNovartisSep 200864
NCT00241020Carcinoma, Hepatocellular3CompletedNovartisOct 2005270
NCT00242541Acromegaly · Mexico4TerminatedNovartisAug 200550
NCT00225979Acromegaly3CompletedNovartisMar 2005100
NCT00171886Acromegaly · Spain4CompletedNovartisMay 200620
NCT00171613Sexual Infantilism4CompletedNovartisOct 200532
NCT00170742Disease · Switzerland3TerminatedNovartisMay 200617
NCT00166725Prostatic Neoplasms · Italy2CompletedNovartis40
NCT00128232Acromegaly3CompletedNovartisAug 2004100
NCT00094146Obesity · United States2CompletedNovartis160
NCT00076362Obesity · United States4CompletedNovartisJul 200560
NCT00050635Neoplasms · United States4CompletedNovartis150
NCT00006269Colorectal Neoplasms · United States3TerminatedNovartisDec 199989
NCT00002253Diarrhea · United States–CompletedNovartis
NCT00002252Diarrhea · United States–CompletedNovartis

How it is read

Names in the registry

  • “Octreotide”, 9 entries
  • “Sandostatin LAR Depot”, 3 entries
  • “Octreotide LAR”, 3 entries
  • “Sandostatin LAR”, 3 entries
  • “Octreotide capsules”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.